Anti-Human CD22 (Epratuzumab Biosimilar)
英诺赛图(InnoCyto)的 Anti-Human CD22 (Epratuzumab Biosimilar)(克隆 Epratuzumab) 为人源 IgG1 抗体,靶向 CD22(别名 BL-CAM 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human CD22 (Epratuzumab Biosimilar)(克隆 Epratuzumab) 为人源 IgG1 抗体,靶向 CD22(别名 BL-CAM 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
502601 | 1 mg | ¥1,695
502602 | 5 mg | ¥4,407
502603 | 20 mg | ¥13,560
Product Details
Product Description|Epratuzumab Biosimilar, CD22 Monoclonal Antibody
Regulatory Status|RUO
Species specificity|Human
Storage Conditions|4ºC
Maximal Shelf Life|12 months
See All Formats|Clone Epratuzumab
Background Information
Epratuzumab is a humanized monoclonal antibody that belongs to the immunoglobulin G1 kappa (IgG1κ) subclass and is engineered to target CD22, a transmembrane glycoprotein expressed primarily on B lymphocytes. Structurally, Epratuzumab is a recombinant glycoprotein with a molecular mass of approximately 145 to 150 kilodaltons (kDa). The molecule is composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds, forming the characteristic Y-shaped antibody configuration typical of IgG immunoglobulins. Each heavy chain contains one variable (VH) domain and three constant regions (CH1-CH3), and each light chain comprises one variable (VL) and one constant (CL) domain. The antibody is produced in mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, ensuring proper glycosylation and folding necessary for biological stability and activity.
The antigen-binding regions of Epratuzumab, located within the complementarity-determining regions (CDRs) of the VH and VL domains, are derived from murine antibody sequences engineered into a human IgG framework to achieve specific recognition of CD22. This epitope binding occurs with high affinity through non-covalent interactions, including hydrogen bonding and van der Waals forces. CD22, a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family, functions as an inhibitory coreceptor that modulates B-cell receptor (BCR) signaling. Upon binding to CD22, Epratuzumab influences intracellular signaling dynamics by promoting receptor internalization and partial modulation of downstream pathways involving calcium mobilization and phosphatase recruitment, such as SHP-1 activation in experimental systems.
The Fc (fragment crystallizable) region of Epratuzumab contributes to its stability and pharmacokinetic properties through interactions with neonatal Fc receptors (FcRn), which extend circulating half-life. As an IgG1 molecule, it can also interact with Fc gamma receptors (FcγRs), enabling potential effector functions like limited antibody-dependent cellular cytotoxicity (ADCC) under defined experimental conditions. Overall, Epratuzumab exemplifies a rationally engineered humanized antibody structure optimized for selective targeting of B-cell surface receptors and modulation of immune-signaling pathways in molecular and cellular studies.
Data Sheets
Cat # Size Price Quantity 5026011 mg Add to Cart5026025 mg Add to Cart50260320 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human CD22 (Epratuzumab Biosimilar)(502601)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-cd22-epratuzumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human CD22 (Epratuzumab Biosimilar)(502601). 产品目录. https://www.suprotek.cn/products/item/anti-human-cd22-epratuzumab-biosimilar.html
@misc{biocsp_item_anti_human_cd22_epratuzumab_biosimilar,
title = {Anti-Human CD22 (Epratuzumab Biosimilar)(502601)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-cd22-epratuzumab-biosimilar.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源